Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA.
Clinical Infectious Diseases (Impact Factor: 8.89). 07/2012; 55 Suppl 1(suppl 1):S58-63. DOI: 10.1093/cid/cis392
Source: PubMed


The prevention of hepatitis C virus (HCV) infection and associated health conditions (eg, cirrhosis and hepatocellular carcinoma)
is a public health priority in the United States. Hepatitis C virus–related morbidity and mortality is increasing at a time
when the advent of highly effective therapies greatly increases opportunities to prevent HCV transmission and disease. In
2010, the Institute of Medicine recommended that national action be taken to address this “underappreciated health concern
for the nation.” In response, in 2011, the US Department of Health and Human Services (HHS) published a viral hepatitis action
plan that guides response to the viral hepatitis epidemic by providing explicit steps to be undertaken by specific HHS agencies
to improve provider training and community education; expand access to testing, care, and treatment; strengthen public health
surveillance; improve HCV preventive services for injection drug users; develop a hepatitis C vaccine; and prevent HCV transmission
in healthcare settings. For all aspects of the action plan, infectious disease specialists and other clinicians assume a key
role in efforts to reduce HCV-related morbidity and mortality. With successful collaboration of the public and private sectors,
the hepatitis C epidemic can be forever silenced.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Prevention of cancer remains the most promising strategy for reducing both its incidence and the mortality due to this disease. For more than four decades, findings from epidemiology, basic research and clinical trials have informed the development of lifestyle and medical approaches to cancer prevention. These include selective oestrogen receptor modulators and aromatase inhibitors for breast cancer, the 5-α-reductase inhibitors finasteride and dutasteride for prostate cancer, and the development of vaccines for viruses that are associated with specific cancers. Future directions include genetic, proteomic and other molecular approaches for identifying pathways that are associated with cancer initiation and development, as well as refining the search for immunologically modifiable causes of cancer.
    Nature Reviews Cancer 11/2012; 12(12). DOI:10.1038/nrc3397 · 37.40 Impact Factor
  • Source
    Grebely · Oser · taylor · dore ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but liver-related morbidity rates remain high, given notoriously low uptake of HCV treatment. Advances in HCV therapy will have a limited impact on the burden of HCV-related disease at the population-level unless barriers to HCV education, screening, evaluation, and treatment are addressed and treatment uptake increases. This review will outline barriers to HCV care in HCV/HIV coinfection, with a particular emphasis on persons who inject drugs, proposing strategies to enhance HCV treatment uptake and outcomes.
    The Journal of Infectious Diseases 03/2013; 207(1):19-25. DOI:10.1093/infdis/jis928 · 6.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Although injection drug use (IDU) and blood transfusions prior to 1992 are well-accepted risk factors for hepatitis C virus (HCV) infection, many studies that evaluated tattooing as a risk factor for HCV infection did not control for a history of IDU or transfusion prior to 1992. In this large, multicenter, case-control study, we analyzed demographic and HCV risk factor exposure history data from 3,871 patients, including 1,930 with chronic HCV infection (HCV RNA-positive) and 1,941 HCV-negative (HCV antibody-negative) controls. Crude and fully adjusted odds ratios (ORs) of tattoo exposure by multivariate logistic regression in HCV-infected versus controls were determined. As expected, IDU (65.9% versus 17.8%; P < 0.001), blood transfusion prior to 1992 (22.3% versus 11.1%; P < 0.001), and history of having one or more tattoos (OR, 3.81; 95% CI, 3.23-4.49; P < 0.001) were more common in HCV-infected patients than in control subjects. After excluding all patients with a history of ever injecting drugs and those who had a blood transfusion prior to 1992, a total of 1,886 subjects remained for analysis (465 HCV-positive patients and 1,421 controls). Among these individuals without traditional risk factors, HCV-positive patients remained significantly more likely to have a history of one or more tattoos after adjustment for age, sex, and race/ethnicity (OR, 5.17; 95% CI, 3.75-7.11; P < 0.001). Conclusion: Tattooing is associated with HCV infection, even among those without traditional HCV risk factors such as IDU and blood transfusion prior to 1992.
    Hepatology 06/2013; 57(6). DOI:10.1002/hep.26245 · 11.06 Impact Factor
Show more